PMID- 28928890
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 8
IP  - 15
DP  - 2017
TI  - Transcatheter arterial chemoembolization (TACE) versus hepatectomy in 
      hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 
      patients.
PG  - 2984-2991
LID - 10.7150/jca.20978 [doi]
AB  - For hepatocellular carcinoma (HCC) patients with macrovascular invasion (MaVI), 
      hepatectomy and transcatheter arterial chemoembolization (TACE) remain the main 
      treatment options in Asia. However, which could achieve better survivals remains 
      controversial. In present study, we conducted a meta-analysis to clarify the 
      survival benefits and safety of hepatectomy versus TACE in HCC patients with 
      MaVI. The PubMed, Cochrane Library and Web of Science databases were searched for 
      eligible studies. There were no prospective studies identified. 8 retrospective 
      studies from Asia with 1683 patients met our inclusion criteria were included in 
      meta-analysis. The overall survival (OS) is higher in hepatectomy group than TACE 
      group (HR=1.61, 95%CI=1.23-2.10, p=0.0005). Hepatectomy was superior over TACE in 
      1-year (OR=2.27, 95%CI=1.26-4.08, p=0.006) and 3-year (OR=3.04, 95%CI=2.17-4.26, 
      p<0.00001) respectively, but not in 5-year (OR=7.34, 95%CI=0.78-68.16, p=0.08) 
      survival rate. Subgroup analysis demonstrated that hepatectomy was superior over 
      TACE for patients with PVTT (HR=1.50, 95%CI=1.14-1.98, p=0.004), but not for 
      patients with HVTT/IVC (HR=2.39, 95%CI=0.88-6.49, p=0.09). There was not 
      significantly difference between two groups in peri-operative mortality. Our 
      results indicated that, compared to TACE, hepatectomy might be a better treatment 
      option for resectable HCC patients with MaVI. Being lack of high-quality studies, 
      more well-designed multi-center randomized trials are needed to confirm our 
      finding.
FAU - Chen, Jinbin
AU  - Chen J
AD  - Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road East, Guangzhou 510060, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, 
      China.
FAU - Huang, Jia
AU  - Huang J
AD  - Department of Obstetrics and Gynaecology, First Affiliated Hospital of Sun 
      Yat-sen University, 58 Zhongshan Road Second, Guangzhou, 510089, P. R. China.
FAU - Chen, Minshan
AU  - Chen M
AD  - Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road East, Guangzhou 510060, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, 
      China.
FAU - Yang, Keli
AU  - Yang K
AD  - Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road East, Guangzhou 510060, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, 
      China.
FAU - Chen, Jiancong
AU  - Chen J
AD  - Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road East, Guangzhou 510060, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, 
      China.
FAU - Wang, Juncheng
AU  - Wang J
AD  - Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road East, Guangzhou 510060, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, 
      China.
FAU - Xu, Li
AU  - Xu L
AD  - Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road East, Guangzhou 510060, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, 
      China.
FAU - Zhou, Zhongguo
AU  - Zhou Z
AD  - Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road East, Guangzhou 510060, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, 
      China.
FAU - Zhang, Yaojun
AU  - Zhang Y
AD  - Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road East, Guangzhou 510060, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South 
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20170825
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC5604450
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Marcovascular invasion
OT  - Meta-analysis.
OT  - Transcatheter arterial chemoembolization
OT  - hepatectomy
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2017/09/21 06:00
MHDA- 2017/09/21 06:01
PMCR- 2017/01/01
CRDT- 2017/09/21 06:00
PHST- 2017/05/11 00:00 [received]
PHST- 2017/07/03 00:00 [accepted]
PHST- 2017/09/21 06:00 [entrez]
PHST- 2017/09/21 06:00 [pubmed]
PHST- 2017/09/21 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - jcav08p2984 [pii]
AID - 10.7150/jca.20978 [doi]
PST - epublish
SO  - J Cancer. 2017 Aug 25;8(15):2984-2991. doi: 10.7150/jca.20978. eCollection 2017.